Research Progress on Dendritic Cells in Hepatocellular Carcinoma Immune Microenvironments

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Dendritic cells (DCs) are critical antigen-presenting cells initiating immune responses.
• DC activation is essential for inducing anti-tumor immunity, including in hepatocellular carcinoma (HCC).
• In HCC, DC inactivation contributes to malignant progression, highlighting the need for DC activation strategies.

Purpose of the Study:

• To review the mechanisms of dendritic cell (DC) activation in hepatocellular carcinoma (HCC).
• To identify regulatory factors involved in DC activation within the HCC context.
• To summarize strategies for activating DCs in HCC immunotherapy.

Main Methods:

• Literature review of mechanisms, regulatory factors, and immunotherapy strategies for DC activation in HCC.
• Analysis of the role of DCs in anti-HCC immunity.
• Synthesis of current knowledge on enhancing DC function for cancer treatment.

Main Results:

• DCs present tumor antigens to T cells, stimulating anti-tumor immune responses.
• Cross-presentation of antigens by DCs to MHC class I molecules induces cytotoxic CD8+ T cell proliferation.
• DC inactivation is implicated in HCC progression, underscoring the importance of their activation.

Conclusions:

• DC activation is a crucial target for effective HCC immunotherapy.
• Understanding DC activation mechanisms and regulatory factors is vital for developing novel therapeutic strategies.
• This review provides a foundation for advancing HCC immunotherapy through DC activation.